Clinical Trials Browser

Completed × INDUSTRY × BI 2536 × Clear all

NCT00243087 2024-12-20

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02211859 2024-12-20

Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

Phase 1 Completed

70 enrolled

Tumor-Agnostic

Neoplasms

NCT00412880 2022-06-22

BI 2536 Second Line Monotherapy in SCLC

Phase 2 Completed

23 enrolled 10 charts

Carcinoma, Small Cell

NCT00376623 2022-06-21

Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer

Phase 2 Completed

96 enrolled 26 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00710710 2022-05-04

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

Phase 2 Completed

89 enrolled 20 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02211833 2014-08-08

Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer

Phase 1 Completed

41 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00701766 2014-05-16

BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia

Phase 2 Completed

71 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00706498 2014-05-16

Phase II Study of BI 2536 in Prostate Cancer

Phase 2 Completed

20 enrolled

Genitourinary

Prostatic Neoplasms